Statin treatment may bring down the chance of later dementia by more than 50%, a domestic Finnish report has ascertained.

“Perturbations in cholesterol metabolic process have previously been connected to dementia evolution,” Dr. Alina Solomon wrote in a poster introduced at the International Conference on Alzheimer’s Disease. All the same, Dr. Solomon, of the University of Kuopio, Finland, observed that not all studies have reasoned that statins bestow a preventive effect against dementia onset.

Doctor. Solomon and her fellows analyzed this question applying information elicited from the national FINRISK report, an extensive, population-based review of cardiovascular risk elements among Finnish citizens. The survey started in 1972 and is conducted every five years. MD. Solomon’s substudy of FINRISK included information about 17,257 citizens who were included in the 1997 and 2002 cohorts, and who were at least 60 years old in 1995, when statins became accessible in Finland.

By the study’s conclusion at 2007, 1,551 of the subjects had acquired dementia and 15,706 hadn’t. Just 18% of those who developed dementia had gotten at least 1 year of statin therapy, while 37% of those who were dementia-free had taken a statin – a substantial deviation.

No meaningful affiliations were ascertained between dementia and the consumption of other cholesterol-lowering medicines, doctor. Solomon stated, indicating that “the effect of statins in dementia is partially unaffiliated of their cholesterol-lowering effect.”

Subjects who acquired dementia likewise had significantly greater baseline total cholesterol and baseline systolic and diastolic blood pressure. But a variable regression framework that controlled for age, gender, education, cholesterol, weight, and blood pressure still ascertained that statins bestowed a 57% risk decrease for dementia across the run of the study.

The determination doesn’t establish that statins prevent dementia. But it does indicate that more reports should research the theme, centering on statin types, doses, and length of treatment, doctor. Solomon stated at the gathering, which was sponsored by the Alzheimer’s Association.

Neither she nor her coinvestigators announced any possible conflict of interest in relation to the report.